Dysfunctional MDM2–p53–PC axis is an important mediator for defective GSIS in type 2 diabetes, and pharmacological interventions targeting this signalling axis, such as inhibition of p53 activity, may be effective for glycaemia control in diabetes. This evidence concerns the gene TP53 and diabetes mellitus.